QuarterHawk — Equity ResearchQuarterHawk — Equity Research

WW International, Inc. (WW)

Consumer Cyclical

No action
Fundamental
2
Sentiment
2
Technical
1

Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3, avgDollarVolume20 $3.79M is below the $5M liquidity floor, and the max overnight gap of 12.58% exceeds the 5% limit; no pullback limit qualifies either (price 10.37 below SMA50 14.38 and SMA200 15.58 with MACD -0.83 < 0 — countertrend, no reclaim) and no breakout stop is viable under the 11.19/12.27 overhead supply, so no entry is emitted.

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

WW International, Inc., formerly Weight Watchers International, is a global provider of weight management and wellness services. The company offers digital subscriptions for health and weight management, as well as consumer products like snack bars and cookbooks. It operates in North America, Europe, and other regions, leveraging its brand through licensing and e-commerce channels.

Fundamental

weak
Fundamental2
Speculative turnaround

WW International shows speculative fundamentals with high leverage and declining revenue, despite recent operational improvements.

Post-bankruptcy, deeply levered subscription business: reported FY2025 profit is a reorganization-gain artifact while the underlying operation has swung to modest operating profit and positive operating cash flow in 2026 against continuing double-digit revenue decline and a 23% subscriber contraction. Cheap on EV/EBITDA at roughly 5x trailing and 3.6x guided FY2026 Adjusted EBITDA, but expensive on risk: ~10.8% secured debt four times the equity value, coverage below one on a trailing basis, negative tangible equity, and live goodwill/trade-name impairment risk. Mixed-to-weak, speculative turnaround; not a clean fundamental buy.

Sentiment

weak
Sentiment2
Flat sentiment

Media sentiment is flat, with no significant retail or catalyst activity, and insider buying not yet reflected in price action.

Q3 2026 earnings (2026-11-05, confidence: announced) is the dominant catalyst and lands neutral: a large EPS beat and 48% clinical-subscription growth were offset by an 11% revenue decline, a weaker-than-expected sales outlook and a stock that traded lower on the print. The media-sentiment delta against the 30-90d baseline is flat (baseline polarity_score about +0.05 versus scoring about +0.08, both measured), retail is indeterminate after two Reddit 403 blocks, and the Red-Flag Screen is clean with no severe or moderate flag fired — the sole constructive leg, a roughly $0.9M six-insider open-market buying cluster dated 2026-11-10, has not been rewarded by the tape and there is no forward-dated catalyst, so the setup stays weak rather than mixed.

Technical

very weak
Technical1
Bearish structure

The stock is in a confirmed downtrend, trading below key moving averages with negative momentum indicators.

Broken structure, not a base. Price 10.37 sits below the SMA20 (13.04), SMA50 (14.38), SMA200 (15.58), EMA9 (12.09) and EMA21 (12.92), and every one of those averages is declining. Momentum is negative and deteriorating: RSI14 36.44, Williams %R -85.05, MACD line -0.83 under its -0.66 signal with the histogram widening to -0.17. ADX14 14.96 shows little trend strength, so this is a gap-driven high-volatility downtrend rather than a clean directional one — ATR14 1.47 is 14.2% of price and the last five sessions contain overnight gaps of 10.8% (11-10 close 12.03 to 11-11 open 13.33) and 12.6% (11-12 close 12.30 to 11-13 open 10.75). Friday printed a 9.50 low before closing 10.37 on 2.02M shares — the heaviest volume of the last 20 sessions — which reads as capitulation into a six-month low, not accumulation. Score 1: bearish/broken structure.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.